AZD0754 for Prostate Cancer
(APOLLO Trial)
Trial Summary
What is the purpose of this trial?
The purpose of this study is to evaluate the safety, tolerability, and antitumour activity of AZD0754 CAR T-cell therapy in participants with metastatic prostate cancer.
Will I have to stop taking my current medications?
The trial protocol does not specify if you need to stop taking your current medications. However, you must continue any medical castration therapy if you are on it, and you cannot receive certain full-dose anticoagulants or recent anticancer therapies close to the study start. It's best to discuss your specific medications with the study team.
What safety data exists for AZD0754 in humans?
How does the drug AZD0754 differ from other prostate cancer treatments?
AZD0754 is unique because it likely targets androgen receptor (AR) signaling, similar to AZD3514, which inhibits both androgen-dependent and independent AR signaling. This approach is particularly important for treating castration-resistant prostate cancer, where traditional hormone therapies fail.13678
Eligibility Criteria
This trial is for individuals with metastatic prostate cancer. Participants should meet specific health criteria to be eligible, but the exact inclusion and exclusion details are not provided.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive AZD0754 CAR T-cell therapy to evaluate safety, tolerability, and antitumour activity
Follow-up
Participants are monitored for safety and effectiveness after treatment
Open-label extension (optional)
Participants may opt into continuation of treatment long-term
Treatment Details
Interventions
- AZD0754
Find a Clinic Near You
Who Is Running the Clinical Trial?
AstraZeneca
Lead Sponsor
Sir Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Dr. Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology
Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Medical Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology